Comparison of patient populations identified by different PD-L1 assays in head and neck squamous cell carcinoma (HNSCC)
Marietta Scott(AstraZeneca (United Kingdom)), Jill Walker(AstraZeneca (United Kingdom)), Hussein ALMasri, Craig Barker(AstraZeneca (United Kingdom)), M. Ratcliffe(AstraZeneca (United Kingdom)), Marlon C. Rebelatto(AstraZeneca (Japan)), Paul W. Scorer(AstraZeneca (United Kingdom)), Sophie Wildsmith(AstraZeneca (United Kingdom))
Cited by 10
Related Papers
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Oncology|2020|502
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
|Annals of Oncology|2020|373
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
|JAMA Oncology|2018|315